graph Evidence gap map comparisons
trastuzumab based treatment
trastuzumab plus endocrine therapy
la/mBC - HER2 positive - 1st Line (L1) 5   
Comparator:  vs trastuzumab plus chemotherapy; 
Risk of bias:  low;   some concerns;   high;  NA;